Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."
You may also be interested in...
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Manufacturing facility concerns likely will derail approval of the oral contraceptive and the antidepressant before the end of the year.
Wyeth Plans To Launch Lybrel, DVS-233 In 2007 After Resolving Manufacturing Issues
Manufacturing facility concerns likely will derail approval of the oral contraceptive and the antidepressant before the end of the year.
Effexor XR Follow-On Desvenlafaxine NDA Submitted
Assuming a standard FDA review, desvenlafaxine could be brought to market more than three years before Effexor XR faces generic competition.